In conclusion, we demonstrate that highly potent NS5A inhibitors disrupt MW formation independent of RNA replication and, therefore, at a very early stage of the viral replication cycle. Although the exact impact of these drugs on NS5A structure remains to be determined, the block of biogenesis of the membranous HCV replication factory likely defines a major mode-of-action of these clinically highly promising direct-acting antiviral drugs. The authors thank Stephanie

Kallis and Ulrike Herian for excellent technical assistance, Jacomine Krijnse-Locker for help with electron microscopy, Simon Reiss for the HA-PI4KIIIα construct, and Charles Rice for the 9E10 antibody and Huh7.5 cells. The PI4KIIIα inhibitor AL-9 was kindly provided by Francesco Peri (Department of Biotechnology and Biosciences, University of Milano-Bicocca, Milano, Italy), Petra Neddermann, and Raffaele De NVP-BGJ398 cell line Francesco (INGM–Istituto

Nazionale Genetica Molecolare Romeo ed Enrica Invernizzi, Milano, Italy). The authors are grateful to the Electron Microscopy Core Facilities at EMBL Heidelberg and Bioquant and the Nikon Imaging Centre, Heidelberg, for providing access to their facilities and expert support. “
“Kirk Lin, Christopher F. Martin, Themistocles Dassopoulos, Silvia D. Degli Esposti, Douglas C. Wolf, Silvia D. Degli Esposti, Dawn B. Beaulieu, Uma Mahadevan. Pregnancy outcomes amongst mothers with inflammatory bowel disease exposed to systemic corticosteroids: results of the PIANO registry. Gastroenterology click here 2014 146;5(Suppl 1):S1 In the above abstract, Lilani Perera should be listed as the 6th author. The citation should correctly be listed as: Kirk Lin, Christopher F. Martin, Themistocles Dassopoulos, Silvia D. Degli Esposti, Douglas C. Wolf, Lilani Perera, Dawn B. Beaulieu, Uma Mahadevan. Pregnancy outcomes amongst mothers with inflammatory GABA Receptor bowel disease exposed to systemic

corticosteroids: results of the PIANO registry. Gastroenterology 2014 146;5(Suppl 1):S1 “
“Gao Q, Zhao YJ, Wang XY et al. Activating mutations in PTPN3 promote cholangiocarcinoma cell proliferation and migration and are associated with tumor recurrence in patients. Gastroenterology 2014;146:1397–1407. In the above article, in the legend for Figure 2, panels (C), (D) and (E) show a detailed view of the residues A90, A211, and L232, respectively. Panel (F) displays the full-length model of PTPN3 protein shows that residue L384 is located in a disorder region between the FERM and PDZ domain. In the main text, on page 1400, Figure 2B should be cited as Figure 2B–E and Figure 2C should be cited as Figure 2F. Also, in Supplementary Figure 1, the validation rate currently listed as “48.4%” should be “51.7%.